Five reasons to invest in TSO3
- There is a growing demand worldwide for low-temperature, medical sterile reprocessing.
- Our superior sterile reprocessing solutions match the market needs and enable sterile reprocessing for challenging devices.
- We seek strong global commercial channel partners.
- We continually pursue new development programs to provide additional revenue streams.
- We are financially responsible and sound.
R.M. (Ric) Rumble, CEO
To Our Valued Shareholders,
The first quarter of 2017 delivered all-time highs for TSO3 in revenue, shipments and installations. Training took place at multiple locations throughout GETINGE’s network of global operations and tangible progress took place within the Company’s GI initiative. All-in-all a very good start to the year.
In the quarter we shipped 36 STERIZONE® VP4 sterilizers to Getinge Infection Control. While this is excellent, the real reward was to see an increased flow of shipments from Getinge’s inventory to its end customers in the US, Canada and Europe. While we cannot disclose details of their business, the rate of installations had a significant up-tick during the first quarter and the end-user hospital list continues to add significant reference institutions.